BR0108930A - Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente - Google Patents

Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente

Info

Publication number
BR0108930A
BR0108930A BR0108930-7A BR0108930A BR0108930A BR 0108930 A BR0108930 A BR 0108930A BR 0108930 A BR0108930 A BR 0108930A BR 0108930 A BR0108930 A BR 0108930A
Authority
BR
Brazil
Prior art keywords
caspase
agent
pro
interest
conjugate
Prior art date
Application number
BR0108930-7A
Other languages
English (en)
Inventor
Paul J Carter
Lewis Gazzard
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR0108930A publication Critical patent/BR0108930A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

"MéTODO DE FORNECIMENTO DE UM AGENTE ATIVO A UM TIPO CELULAR DE INTERESSE, COMPOSIçãO FARMACêUTICA, PRó-DROGA ATIVADA POR CASPASE, KIT, MéTODO DE TRATAMENTO DE MAMìFEROS, USO DE UM CONJUGADO DE CASPASE E USO DE UM PRó-AGENTE". A presente invenção proporciona métodos inovadores para o fornecimento localizado de agentes farmacêuticos através da administração de um conjugado de caspase que se dirige a um tipo celular de interesse e da administração adicional de um pró-agente que é convertido localmente, na presença da caspase, em um agente ativo. A presente invenção proporciona, ainda, agentes direcionadores inovadores que compreendem uma caspase, bem como pró-drogas inovadoras que compreendem uma porção de pró-droga clivável por caspase. A presente invenção também fornece composições farmacêuticas, bem como métodos de tratamento que compreendem os conjugados de caspase e pró-drogas de acordo com a presente invenção
BR0108930-7A 2000-02-24 2001-02-22 Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente BR0108930A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18477900P 2000-02-24 2000-02-24
PCT/US2001/005709 WO2001062300A2 (en) 2000-02-24 2001-02-22 Caspase activated prodrugs therapy

Publications (1)

Publication Number Publication Date
BR0108930A true BR0108930A (pt) 2002-12-10

Family

ID=22678303

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108930-7A BR0108930A (pt) 2000-02-24 2001-02-22 Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente

Country Status (15)

Country Link
US (1) US20070104719A1 (pt)
EP (1) EP1257296A2 (pt)
JP (1) JP2003523407A (pt)
KR (1) KR20020082227A (pt)
CN (1) CN1406137A (pt)
AU (1) AU783679B2 (pt)
BR (1) BR0108930A (pt)
CA (1) CA2399255A1 (pt)
HU (1) HUP0300024A2 (pt)
IL (1) IL150992A0 (pt)
MX (1) MXPA02007939A (pt)
NZ (1) NZ520458A (pt)
PL (1) PL358187A1 (pt)
WO (1) WO2001062300A2 (pt)
ZA (1) ZA200206105B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
WO2002043773A2 (en) * 2000-12-01 2002-06-06 The Johns Hopkins University Tissue specific prodrugs
CA2475247C (en) * 2002-02-07 2015-08-04 Massachusetts Institute Of Technology Anti-pathogen treatments
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AU2004248138B2 (en) 2003-05-29 2009-09-03 The Scripps Research Institute Targeted delivery to legumain-expressing cells
CA2679643A1 (en) * 2007-03-09 2008-09-18 The University Of British Columbia Procaspase 8-mediated disease targeting
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8703114B2 (en) * 2008-05-22 2014-04-22 Ramot At Tel-Aviv University Ltd. Conjugate of a polymer, an anti-angiogenesis agent and a targeting moiety, and uses thereof in the treatment of bone related angiogenesis conditions
US8586019B2 (en) 2008-05-22 2013-11-19 Ramot At Tel-Aviv University Ltd. Conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases
EP2303288A4 (en) 2008-05-22 2015-04-22 Univ Ramot CONJUGATES OF A POLYMER, A BISPHOSPHONATE AND AN ANTI-ANGIOGENESE MEDIUM AND ITS USE IN THE TREATMENT AND CONTROL OF ILLNESSES RELATED TO BONE
TW201006485A (en) 2008-06-03 2010-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2726087A1 (en) 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
WO2011028811A2 (en) 2009-09-01 2011-03-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
US20110076709A1 (en) * 2009-09-28 2011-03-31 Quest Diagnostics Investments Incorporated Method for the Diagnosis of Leukemia Using Caspase-3
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
CA2816041C (en) * 2010-12-29 2019-01-08 Arrowhead Research Corporation In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
KR20130110218A (ko) 2011-03-02 2013-10-08 한국과학기술연구원 방사선 또는 자외선 조사에 의해 활성화되는 항암제 전구체 및 이의 용도
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
CN104244988A (zh) 2012-03-05 2014-12-24 雷蒙特亚特特拉维夫大学有限公司 结合治疗活性剂的聚合物、其制备方法以及其用途
TW202037609A (zh) 2012-11-01 2020-10-16 美商艾伯維有限公司 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
CN106456799B (zh) * 2014-06-03 2020-05-22 江苏佳瑞生物技术有限公司 肽-药物偶联物
US9593080B1 (en) 2014-06-11 2017-03-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Triazabutadienes as cleavable cross-linkers
WO2015191735A1 (en) 2014-06-11 2015-12-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Water-soluble triazabutadienes
US10125105B2 (en) 2014-06-11 2018-11-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Triazabutadienes as cleavable cross-linkers
US9775914B2 (en) 2014-11-20 2017-10-03 Pharosgen Co., Ltd. Prodrugs activated by caspase
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US10954195B2 (en) 2015-08-11 2021-03-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted triazenes protected from degradation by carboxylation of N1
US11813336B2 (en) * 2016-05-04 2023-11-14 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
US11339129B2 (en) 2016-07-29 2022-05-24 Arizona Board of Regents on behalf of the University of Arizon Triazabutadienes as cleavable cross-linkers
JP7404252B2 (ja) * 2017-11-08 2023-12-25 ヤフェイ シャンハイ バイオロジー メディスン サイエンス アンド テクノロジー カンパニー リミテッド 生体分子のコンジュゲートおよびその使用
CN114728073B (zh) * 2019-09-19 2024-12-27 思进股份有限公司 药物从生物活性化合物的内化缀合物的选择性释放
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) * 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
WO1999006072A1 (en) * 1997-07-30 1999-02-11 Boehringer Mannheim Corporation Cyclized prodrugs
WO1999029721A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
US6379950B1 (en) * 1998-01-09 2002-04-30 Thomas Jefferson University Recombinant, active caspases and uses thereof
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
US6833373B1 (en) * 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
GB2360771A (en) * 2000-03-28 2001-10-03 Antisoma Res Ltd Compounds for targeting
EP1286700A2 (en) * 2000-06-01 2003-03-05 Universite Catholique De Louvain Tumor activated prodrug compounds

Also Published As

Publication number Publication date
WO2001062300A2 (en) 2001-08-30
HUP0300024A2 (en) 2003-05-28
US20070104719A1 (en) 2007-05-10
WO2001062300A3 (en) 2002-04-25
AU4166701A (en) 2001-09-03
EP1257296A2 (en) 2002-11-20
MXPA02007939A (es) 2003-02-10
CA2399255A1 (en) 2001-08-30
ZA200206105B (en) 2003-07-31
IL150992A0 (en) 2003-02-12
PL358187A1 (en) 2004-08-09
NZ520458A (en) 2005-02-25
JP2003523407A (ja) 2003-08-05
AU783679B2 (en) 2005-11-24
CN1406137A (zh) 2003-03-26
KR20020082227A (ko) 2002-10-30

Similar Documents

Publication Publication Date Title
BR0108930A (pt) Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente
UA91512C2 (ru) Коньюгати олигомеров инсулина, их композиция (варианты) и применение
BR0316050A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
SG156624A1 (en) Organo-gel formulations for therapeutic applications
BR0108173A (pt) Composições farmacêuticas de toxina de botulina
BR9815442A (pt) Liberação terapêutica dirigida de compostos de vitamina d
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
EE200200578A (et) Antihüpertensiivsete ja antiangiogeensete ainete terapeutilised kombinatsioonid
ATE298562T1 (de) Hydrogelpartikel formulierungen
DE60326887D1 (de) Pharmazeutische zusammensetzungen enthaltend botulinumtoxin und humanes serum-albumin
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
ATE337019T1 (de) Geladene lipide und deren verwendung
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
PT1033981E (pt) Formulacoes e metodos para reduzir a toxicidade de agentes antineoplasicos
BR0109266A (pt) Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto
BR0012082A (pt) Formulação farmacêutica para administração compreendendo morfina e seu uso
EP1819227A4 (en) PHARMACEUTICAL FORMULATIONS OF DECITABIN
BR9914419A (pt) Terapia para melhoria da percepção
WO2002087465A3 (en) Compositions and methods of double-targeting virus infections and cancer cells
PT1073467E (pt) Formulacoes de co-solvente que compreendem um composo de vitamina d.
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
BRPI0416275A (pt) métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
WO2001034614A3 (en) Compositions and methods for double-targeting virus infections and targeting cancer cells

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A,10A E 11A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.

B15K Others concerning applications: alteration of classification

Ipc: C07K 16/32 (2006.01), A61K 47/68 (2017.01), B82Y 5